<!DOCTYPE html>
<html>
<head>
<title>Biktarvy, INN-Bictegravir/Emtricitabine/Tenofovir Alafenamide</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge">
</head>
<body>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:274pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">ANNEX I </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:175pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">SUMMARY OF PRODUCT CHARACTERISTICS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:214pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:286pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy 30 mg/120 mg/15 mg film-coated tablets  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy 50 mg/200 mg/25 mg film-coated tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy 30 mg/120 mg/15 mg film-coated tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each film-coated tablet contains bictegravir sodium equivalent to 30 mg of bictegravir, 120 mg of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">emtricitabine, and tenofovir alafenamide fumarate equivalent to 15 mg of tenofovir alafenamide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy 50 mg/200 mg/25 mg film-coated tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each film-coated tablet contains bictegravir sodium equivalent to 50 mg of bictegravir, 200 mg of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">emtricitabine, and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Film-coated tablet (tablet). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy 30 mg/120 mg/15 mg film-coated tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pink, capsule-shaped, film-coated </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tablet, debossed with &#x201c;BVY&#x201d; on one side and a score line on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">other side of the tablet. Each tablet is approximately 14 mm x 6 mm.  The score line is only to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">facilitate breaking for ease of swallowing and not to divide into equal doses. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy 50 mg/200 mg/25 mg film-coated tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Purplish-brown, capsule-shaped, film-coated </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tablet debossed with &#x201c;GSI&#x201d; on one side and &#x201c;9883&#x201d; on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the other side of the tablet.  Each tablet is approximately 15 mm </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xf0b4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 8 mm. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and paediatric patients at least 2 years of age and weighing at least 14 kg without present or past </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therapy should be initiated by a physician experienced in the management of HIV infection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric patients at least 2 years of age and weighing at least 14</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">kg to less than 25 kg </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">One 30 mg/120 mg/15 mg tablet to be taken once daily. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adults and paediatric patients weighing at least 25 kg </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">One 50 mg/200 mg/25 mg tablet to be taken once daily. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:286pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Missed doses </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If the patient misses a dose of Biktarvy within 18 hours of the time it is usually taken, the patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should take Biktarvy as soon as possible and resume the normal dosing schedule.  If a patient misses a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose of Biktarvy by more than 18 hours, the patient should not take the missed dose and simply </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">resume the usual dosing schedule. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If the patient vomits within 1 hour of taking Biktarvy another tablet should be taken.  If a patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vomits more than 1 hour after taking Biktarvy they do not need to take another dose of Biktarvy until </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the next regularly scheduled dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment of Biktarvy is required in patients </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aged &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 65 years (see sections 4.8 and 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment of Biktarvy is required in patients with mild (Child-Pugh Class A) or moderate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Child-Pugh Class B) hepatic impairment.  Biktarvy has not been studied in patients with severe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatic impairment (Child-Pugh Class C), therefore Biktarvy is not recommended for use in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with severe hepatic impairment (see sections 4.4 and 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment of Biktarvy is required in patients weighing </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 35 kg with estimated creatinine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clearance (CrCl) </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 30 mL/min. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment of Biktarvy is required in adult patients with end stage renal disease (estimated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine clearance &lt; 15 mL/minute) who are receiving chronic haemodialysis.  However, Biktarvy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should generally be avoided and only be used in these patients if the potential benefits are considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to outweigh the potential risks (see sections 4.4 and 5.2).  On days of haemodialysis, Biktarvy should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be administered after completion of haemodialysis treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Initiation of Biktarvy should be avoided in patients with estimated creatinine clearance </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;15</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> mL/min </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and &lt; 30 mL/min, or &lt; 15 mL/min who are not receiving chronic haemodialysis, as the safety of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy has not been established in these populations (see section 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No data are available to make dose recommendations in patients weighing &lt; 35 kg with renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">impairment or in paediatric patients less than 18 years with end stage renal disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Biktarvy in children less than 2 years of age or weighing less than 14 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have not yet been established.  No data are available. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Oral use. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy can be taken with or without food (see section 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Due to the bitter taste, it is recommended that the film-coated tablets should not be chewed or crushed.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For patients who are unable to swallow the tablet whole, the tablet may be split in half and both halves </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">taken one after the other, ensuring that the full dose is taken immediately. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Co-administration with rifampicin and St. </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">John&#x2019;s </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">wort (</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypericum perforatum</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:286pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients co-infected with HIV and hepatitis B or C virus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">severe and potentially fatal hepatic adverse reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are limited safety and efficacy data for Biktarvy in patients co-infected with HIV-1 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis C virus (HCV).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy contains tenofovir alafenamide, which is active against hepatitis B virus (HBV). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinuation of Biktarvy therapy in patients co-infected with HIV and HBV may be associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with severe acute exacerbations of hepatitis.  Patients co-infected with HIV and HBV who discontinue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy should be closely monitored with both clinical and laboratory follow-up for at least several </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">months after stopping treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Liver disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Biktarvy in patients with significant underlying liver disorders have not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">been established. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequency of liver function abnormalities during combination antiretroviral therapy (CART) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be monitored according to standard practice.  If there is evidence of worsening liver disease in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">such patients, interruption or discontinuation of treatment must be considered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Weight and metabolic parameters </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapy.  Such changes may in part be linked to disease control and lifestyle.  For lipids, there is in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">some cases evidence for a treatment effect, while for weight gain there is no strong evidence relating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">this to any particular treatment.  For monitoring of blood lipids and glucose, reference is made to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">established HIV treatment guidelines.  Lipid disorders should be managed as clinically appropriate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mitochondrial dysfunction following exposure </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pronounced with stavudine, didanosine and zidovudine.  There have been reports of mitochondrial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dysfunction in HIV negative infants exposed </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and/or postnatally to nucleoside analogues; these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have predominantly concerned treatment with regimens containing zidovudine.  The main adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(hyperlactatemia, hyperlipasemia).  These events have often been transitory.  Late onset neurological </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour).  Whether such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">neurological disorders are transient or permanent is currently unknown.  These findings should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considered for any child exposed </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> to nucleos(t)ide analogues, who present with severe clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">findings of unknown aetiology, particularly neurologic findings.  These findings do not affect current </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">national recommendations to use antiretroviral therapy in pregnant women to prevent vertical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">transmission of HIV. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immune Reactivation Syndrome </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In HIV infected patients with severe immune deficiency at the time of institution of CART, an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serious clinical conditions, or aggravation of symptoms.  Typically, such reactions have been observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">within the first few weeks or months of initiation of CART.  Relevant examples include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pneumocystis </span></i></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:286pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">jirovecii</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> pneumonia.  Any inflammatory symptoms should be evaluated and treatment instituted when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Autoimmune disorders (such as Graves&#x2019; disease</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and autoimmune hepatitis) have also been reported to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occur in the setting of immune reactivation; however, the reported time to onset is more variable and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">these events can occur many months after initiation of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Opportunistic infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients should be advised that Biktarvy or any other antiretroviral therapy does not cure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV infection and that they may still develop opportunistic infections and other complications of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV infection.  Therefore, patients should remain under close clinical observation by physicians </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">experienced in the treatment of patients with HIV associated diseases. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Osteonecrosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reported particularly in patients with advanced HIV disease and/or long-term exposure to CART.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients should be advised to seek medical advice if they experience joint aches and pain, joint </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">stiffness or difficulty in movement. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nephrotoxicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Post-marketing cases of renal impairment, including acute renal failure and proximal renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tubulopathy have been reported with tenofovir alafenamide-containing products.  A potential risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nephrotoxicity resulting from chronic exposure to low levels of tenofovir due to dosing with tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alafenamide cannot be excluded (see section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is recommended that renal function is assessed in all patients prior to, or when initiating, therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with Biktarvy and that it is also monitored during therapy in all patients as clinically appropriate.  In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients who develop clinically significant decreases in renal function, or evidence of proximal renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tubulopathy, discontinuation of Biktarvy should be considered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with end stage renal disease on chronic haemodialysis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy should generally be avoided but may be used in adults with end stage renal disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(estimated CrCl &lt; 15 mL/min) on chronic haemodialysis if the potential benefits outweigh the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">potential risks (see section 4.2).  In a study of emtricitabine + tenofovir alafenamide in combination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with elvitegravir + cobicistat as a fixed-dose combination tablet (E/C/F/TAF) in HIV-1 infected adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with end stage renal disease (estimated CrCl &lt; 15 mL/min) on chronic haemodialysis, efficacy was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintained through 96 weeks but emtricitabine exposure was significantly higher than in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">normal renal function.  Efficacy was also maintained in the extension phase of the study in which 10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients switched to Biktarvy for 48 weeks.  Although no additional adverse reactions were identified, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the implications of increased emtricitabine exposure remain uncertain (see sections 4.8 and 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Co-administration of other medicinal products </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy should not be co-administered simultaneously with magnesium/aluminium-containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antacids or iron supplements under fasted conditions.  Biktarvy should be administered at least 2 hours </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">before, or with food 2 hours after antacids containing magnesium and/or aluminium.  Biktarvy should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be administered at least 2 hours before iron supplements, or taken together with food (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Some medicinal products are not recommended for co-administration with Biktarvy: atazanavir, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">carbamazepine, ciclosporin (IV or oral use), oxcarbazepine, phenobarbital, phenytoin, rifabutin, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rifapentine, or sucralfate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:286pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy should not be co-administered with other antiretroviral medicinal products. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reductions in bone mineral density (BMD &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 4%) of the spine and total body less head (TBLH) have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">been reported in patients aged between 3 to &lt; 12 years who received tenofovir alafenamide-containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products for 48 weeks (see section 4.8).  The long-term effects of changes in BMD on the growing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bone, including the risk of fracture, are uncertain.  A multidisciplinary approach is recommended to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decide the appropriate monitoring during treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipients</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2018;sodium</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">free&#x2019;.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interaction studies have only been performed in adults. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy should not be administered concomitantly with medicinal products containing tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alafenamide, tenofovir disoproxil, lamivudine or adefovir dipivoxil used for the treatment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HBV infection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is a substrate of CYP3A and UGT1A1.  Co-administration of bictegravir and medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products that potently induce both CYP3A and UGT1A1, such as rifampicin or St. </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">John&#x2019;s wort</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significantly decrease plasma concentrations of bictegravir, which may result in a loss of therapeutic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect of Biktarvy and development of resistance, therefore co-administration is contraindicated (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.3).  Co-administration of bictegravir with medicinal products that potently inhibit both </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CYP3A and UGT1A1, such as atazanavir, may significantly increase plasma concentrations of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bictegravir, therefore co-administration is not recommended.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir is both a P-gp and a BCRP substrate.  The clinical relevance of this feature is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">established.  Therefore, caution is recommended when bictegravir is combined with medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products known to inhibit P-gp and/or BCRP (e.g. macrolides, ciclosporin, verapamil, dronedarone, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glecaprevir/pibrentasvir) (see also table below). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibits organic cation transporter 2 (OCT2) and multidrug and toxin extrusion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">transporter 1 (MATE1) </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">.  Co-administration of Biktarvy with the OCT2 and MATE1 substrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metformin did not result in a clinically significant increase in metformin exposure.  Biktarvy may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">co-administered with substrates of OCT2 and MATE1.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is not an inhibitor or inducer of CYP </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Emtricitabine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CYP-mediated interactions involving emtricitabine with other medicinal products is low.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Co-administration of emtricitabine with medicinal products that are eliminated by active tubular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">secretion may increase concentrations of emtricitabine, and/or the co-administered medicinal product.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Medicinal products that decrease renal function may increase concentrations of emtricitabine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tenofovir alafenamide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tenofovir alafenamide is transported by P-glycoprotein (P-gp) and breast cancer resistance protein </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(BCRP).  Co-administration of Biktarvy with medicinal products that strongly affect P-gp and BCRP </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:286pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">activity may lead to changes in tenofovir alafenamide absorption.  Medicinal products that induce </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">P-gp activity (e.g. rifabutin, carbamazepine, phenobarbital) are expected to decrease the absorption of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may lead to loss of therapeutic effect of Biktarvy and development of resistance.  Co-administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy with other medicinal products that inhibit P-gp and BCRP may increase the absorption and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">plasma concentration of tenofovir alafenamide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tenofovir alafenamide is not an inhibitor or inducer of CYP3A</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> in vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Other interactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interactions between Biktarvy or its individual component(s) and co-administered medicinal products </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are listed in Table </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 below (increase is indicated as &#x201c;&#x2191;&#x201d;, decrease as &#x201c;&#x2193;&#x201d; and no change as &#x201c;&#x2194;&#x201d;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">; all No </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Effect Boundaries are 70%-143%).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 1: Interactions between Biktarvy or its individual component(s) and other medicinal </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">products </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:100pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Medicinal product by </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:90pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">therapeutic areas/possible </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:92pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">mechanism of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:236pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Effects on medicinal product </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:284pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">levels. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:233pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Mean percent change in AUC, </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:276pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">C</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">max</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">, C</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">min</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:386pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Recommendation concerning </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:380pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">co-administration with Biktarvy </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:76pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">HERBAL PRODUCTS</span></i></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">St. </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">John&#x2019;s wort (</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Hypericum </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:76pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">perforatum</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Induction of CYP3A, UGT1A1, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">and P-gp)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Interaction not studied with any of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">the components of Biktarvy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration may decrease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">bictegravir and tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">alafenamide plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">concentrations.</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration with St. John</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2019;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">wort is contraindicated, due to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">effect of St. </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">John&#x2019;s wort on t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">he </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">bictegravir component of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Biktarvy.</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:76pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">ANTI-INFECTIVES </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Antimycobacterials </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Rifampicin (600 mg once daily),  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">1</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Induction of CYP3A, UGT1A1, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">and P-gp) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 75% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 28% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Interaction not studied with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">tenofovir alafenamide.   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration of rifampicin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">may decrease tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">alafenamide plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">concentrations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">contraindicated due to the effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">of rifampicin on the bictegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">component of Biktarvy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Rifabutin (300 mg once daily),  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">1</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Induction of CYP3A and P-gp) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 38% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 56% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 20% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Interaction not studied with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">tenofovir alafenamide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration of rifabutin may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">decrease tenofovir alafenamide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">plasma concentrations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">recommended due to the expected </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">decrease of tenofovir alafenamide. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:286pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:100pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Medicinal product by </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:90pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">therapeutic areas/possible </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:92pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">mechanism of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:236pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Effects on medicinal product </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:284pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">levels. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:233pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Mean percent change in AUC, </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:90pt;left:276pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">C</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">max</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">, C</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">min</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:386pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Recommendation concerning </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:380pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">co-administration with Biktarvy </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Rifapentine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Induction of CYP3A and P-gp)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Interaction not studied with any of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">the components of Biktarvy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration of rifapentine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">may decrease bictegravir and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">tenofovir alafenamide plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">concentrations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">HIV-1 antiviral agents </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Atazanavir (300 mg once daily), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Cobicistat (150 mg once daily), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">1</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Inhibition of CYP3A, UGT1A1, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">and P-gp/BCRP) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 306% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Atazanavir (400 mg once daily), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">1</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Inhibition of CYP3A and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">UGT1A1)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 315% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<img style="position:absolute;top:254pt;left:71pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:73pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:76pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:78pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:81pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:83pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:85pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:88pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:90pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:93pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:95pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:97pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:100pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:102pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:105pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:107pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:109pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:112pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:114pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:117pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:119pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:121pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:124pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:126pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:129pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:131pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:133pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:136pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:138pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:141pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:143pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:145pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:148pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:150pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:153pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:155pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:157pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:160pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:162pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:165pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:167pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:169pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:172pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:174pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:177pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:179pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:181pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:184pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:186pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:189pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:191pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:193pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:196pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:198pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:201pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:203pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:205pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:208pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:210pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:213pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:215pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:217pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:220pt;width:1pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAMAAAABCAIAAACUgoPjAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkgAEAABQAAnR7pWQAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:221pt;width:0pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGNkYGAAAAAIAAI76MGHAAAAAElFTkSuQmCC">
<img style="position:absolute;top:254pt;left:221pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:224pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:226pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:229pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:231pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:233pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:236pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:238pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:241pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:243pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:245pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:248pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:250pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:253pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:255pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:257pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:260pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:262pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:265pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:267pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:269pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:272pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:274pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:277pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:279pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:281pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:284pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:286pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:289pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:291pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:293pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:296pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:298pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:301pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:303pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:305pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:308pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:310pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:313pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:315pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:317pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:320pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:322pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:325pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:327pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:329pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:332pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:334pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:337pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:339pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:341pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:344pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:346pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:349pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:351pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:353pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:356pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:358pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:361pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:363pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:365pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:368pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:370pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:254pt;left:373pt;width:0pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGNkYGAAAAAIAAI76MGHAAAAAElFTkSuQmCC">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Hepatitis C virus antiviral agents </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Ledipasvir/Sofosbuvir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(90 mg/400 mg once daily), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir/Emtricitabine/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Tenofovir alafenamide</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Emtricitabine: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Tenofovir alafenamide: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Ledipasvir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Sofosbuvir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Sofosbuvir metabolite GS-331007: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">No dose adjustment is required </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">upon co-administration. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:286pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:100pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Medicinal product by </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:90pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">therapeutic areas/possible </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:92pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">mechanism of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:236pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Effects on medicinal product </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:284pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">levels. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:233pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Mean percent change in AUC, </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:90pt;left:276pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">C</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">max</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">, C</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">min</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:386pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Recommendation concerning </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:380pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">co-administration with Biktarvy </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Sofosbuvir/Velpatasvir/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Voxilaprevir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(400/100/100 + 100 mg</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">daily), Bictegravir/Emtricitabine/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Tenofovir alafenamide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Inhibition of P-gp/BCRP) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Emtricitabine: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Tenofovir alafenamide: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 57% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 28% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Sofosbuvir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Sofosbuvir metabolite GS-331007: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Velpatasvir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Voxilaprevir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">No dose adjustment is required </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">upon co-administration. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Antifungals</span></b><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Voriconazole (300 mg twice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">daily), Bictegravir</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">1</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Inhibition of CYP3A) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 61% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">No dose adjustment is required </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">upon co-administration.</span><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Itraconazole </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Posaconazole  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Inhibition of P-gp/BCRP) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Interaction not studied with any of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">the components of Biktarvy.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration of itraconazole </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">or posaconazole may increase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">bictegravir</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">plasma concentrations. </span></p>
<img style="position:absolute;top:530pt;left:71pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:73pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:76pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:78pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:81pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:83pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:85pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:88pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:90pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:93pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:95pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:97pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:100pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:102pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:105pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:107pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:109pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:112pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:114pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:117pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:119pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:121pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:124pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:126pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:129pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:131pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:133pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:136pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:138pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:141pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:143pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:145pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:148pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:150pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:153pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:155pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:157pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:160pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:162pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:165pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:167pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:169pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:172pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:174pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:177pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:179pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:181pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:184pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:186pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:189pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:191pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:193pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:196pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:198pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:201pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:203pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:205pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:208pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:210pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:213pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:215pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:217pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:220pt;width:1pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAMAAAABCAIAAACUgoPjAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkgAEAABQAAnR7pWQAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:221pt;width:0pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGNkYGAAAAAIAAI76MGHAAAAAElFTkSuQmCC">
<img style="position:absolute;top:530pt;left:221pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:224pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:226pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:229pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:231pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:233pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:236pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:238pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:241pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:243pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:245pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:248pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:250pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:253pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:255pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:257pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:260pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:262pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:265pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:267pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:269pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:272pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:274pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:277pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:279pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:281pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:284pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:286pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:289pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:291pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:293pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:296pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:298pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:301pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:303pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:305pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:308pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:310pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:313pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:315pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:317pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:320pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:322pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:325pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:327pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:329pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:332pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:334pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:337pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:339pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:341pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:344pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:346pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:349pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:351pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:353pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:356pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:358pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:361pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:363pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:365pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:368pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:370pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:530pt;left:373pt;width:0pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAIAAACQd1PeAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAADElEQVR4nGNkYGAAAAAIAAI76MGHAAAAAElFTkSuQmCC">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Macrolides</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Azithromycin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Clarithromycin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Inhibition of P-gp) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Interaction not studied.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration of azithromycin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">or clarithromycin may increase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">bictegravir plasma concentrations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Caution is recommended due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">the potential effect of these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">medicinal products on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">bictegravir component of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Biktarvy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:100pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Medicinal product by </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:90pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">therapeutic areas/possible </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:92pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">mechanism of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:236pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Effects on medicinal product </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:284pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">levels. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:233pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Mean percent change in AUC, </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:90pt;left:276pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">C</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">max</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">, C</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">min</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:386pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Recommendation concerning </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:380pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">co-administration with Biktarvy </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:76pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">ANTICONVULSANTS </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Carbamazepine (titrated from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">100 mg to 300 mg twice a day), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Emtricitabine/Tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">alafenamide</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">4</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Induction of CYP3A, UGT1A1, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">and P-gp) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Tenofovir alafenamide: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 54% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 57% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Interaction not studied with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">bictegravir.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">carbamazepine may decrease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">bictegravir</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">plasma concentrations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Oxcarbazepine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Phenobarbital </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Phenytoin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Induction of CYP3A, UGT1A1, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">and P-gp) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Interaction not studied with any of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">the components of Biktarvy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">oxcarbazepine, phenobarbital, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">phenytoin may decrease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">bictegravir</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">and tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">alafenamide plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">concentrations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:76pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">ANTACIDS, SUPPLEMENTS AND BUFFERED MEDICINES </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Magnesium/aluminium-containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">antacid suspension (20 mL single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">dose</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">5</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">), Bictegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Chelation with polyvalent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">cations) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir (antacid suspension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2 hours prior, fasted): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 52% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 58% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir (antacid suspension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">after 2 hours, fasted): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir (simultaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">administration, fasted): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 79% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 80% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir (simultaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">administration with food): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 47% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 49% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Biktarvy should not be taken </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">simultaneously with supplements </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">containing magnesium and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">aluminium due to the expected </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">substantial decrease of bictegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">exposure (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Biktarvy should be administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">at least 2 hours before, or with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">food 2 hours after antacids </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">containing magnesium and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">aluminium. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Ferrous fumarate (324 mg single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">dose), Bictegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Chelation with polyvalent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">cations) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir (simultaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">administration, fasted): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 63% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 71% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir (simultaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">administration with food): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 25% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Biktarvy should be administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">at least 2 hours before iron </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">supplements, or taken together </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">with food. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Calcium carbonate (1,200 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">single dose), Bictegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Chelation with polyvalent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">cations) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir (simultaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">administration, fasted): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 33% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 42% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir (simultaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">administration with food): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Biktarvy and calcium-containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">supplements can be taken </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">together, without regard to food. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">11 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:100pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Medicinal product by </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:90pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">therapeutic areas/possible </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:92pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">mechanism of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:236pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Effects on medicinal product </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:284pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">levels. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:233pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Mean percent change in AUC, </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:90pt;left:276pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">C</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">max</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">, C</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">min</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:386pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Recommendation concerning </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:380pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">co-administration with Biktarvy </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Sucralfate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Chelation with polyvalent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">cations) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Interaction not studied with any of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">the components of Biktarvy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration may decrease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">bictegravir plasma concentrations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:76pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">ANTIDEPRESSANTS</span></i></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Sertraline (50 mg single dose), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Tenofovir alafenamide</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">6</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Tenofovir alafenamide: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Sertraline: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">No interaction is expected with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">bictegravir and emtricitabine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">No dose adjustment is required </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">upon co-administration. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:76pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">IMMUNOSUPPRESSANTS</span></i></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Ciclosporin (IV or oral use) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(P-gp inhibition) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Interaction not studied with any of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">the components of Biktarvy.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration of ciclosporin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(IV or oral use) is expected to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">increase plasma concentrations of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">both bictegravir and tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">alafenamide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Co-administration of ciclosporin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(IV or oral use) is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">recommended.  If the combination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">is needed, clinical and biological </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">monitoring, notably renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">function, is recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:76pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">ORAL ANTI-DIABETICS </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Metformin (500 mg twice daily), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir/Emtricitabine/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Tenofovir alafenamide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(Inhibition of OCT2/MATE1)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Metformin: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 39% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 36% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">No dose adjustment is required </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">upon co-administration</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">with normal renal function. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">In patients with moderate renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">impairment, close monitoring </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">should be considered when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">starting co-administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">bictegravir with metformin, due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">the increased risk for lactic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">acidosis in these patients.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">A dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">adjustment of metformin should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">be considered if required.</span><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:76pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">ORAL CONTRACEPTIVES </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Norgestimate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(0.180/0.215/0.250 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">daily)/ Ethinylestradiol (0.025 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">once daily), Bictegravir</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">1</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Norelgestromin: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Norgestrel: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Ethinylestradiol: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: &#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">No dose adjustment is required </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">upon co-administration. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Norgestimate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(0.180/0.215/0.250 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">daily), Ethinylestradiol (0.025 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">once daily), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Emtricitabine/Tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">alafenamide</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">4</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<img style="position:absolute;top:590pt;left:71pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:73pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:76pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:78pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:81pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:83pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:85pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:88pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:90pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:93pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:95pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:97pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:100pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:102pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:105pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:107pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:109pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:112pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:114pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:117pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:119pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:121pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:124pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:126pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:129pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:131pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:133pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:136pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:138pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:141pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:143pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:145pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:148pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:150pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:153pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:155pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:157pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:160pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:162pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:165pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:167pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:169pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:172pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:174pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:177pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:179pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:181pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:184pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:186pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:189pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:191pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:193pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:196pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:198pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:201pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:203pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:205pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:208pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:210pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:213pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:215pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:217pt;width:2pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAYAAAABCAIAAAByq0inAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkwAAAACYAAtzDMkYAAAAASUVORK5CYII=">
<img style="position:absolute;top:590pt;left:220pt;width:1pt;height:0pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAAMAAAABCAIAAACUgoPjAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAC0lEQVR4nGNkgAEAABQAAnR7pWQAAAAASUVORK5CYII=">
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:100pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Medicinal product by </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:90pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">therapeutic areas/possible </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:92pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">mechanism of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:236pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Effects on medicinal product </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:284pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">levels. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:233pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Mean percent change in AUC, </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:90pt;left:276pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">C</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">max</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">, C</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">min</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:386pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Recommendation concerning </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:380pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">co-administration with Biktarvy </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:76pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">SEDATIVES/HYPNOTICS</span></i></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Midazolam (2 mg, oral syrup, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">single dose), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Bictegravir/Emtricitabine/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Tenofovir alafenamide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Midazolam: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:227pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">: </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">No dose adjustment is required </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:379pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">upon co-administration. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">This study was conducted using</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">bictegravir 75 mg single dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">This study was conducted using bictegravir/emtricitabine/tenofovir alafenamide 75/200/25 mg once daily. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV infected </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">This study was conducted using emtricitabine/tenofovir alafenamide 200/25 mg once daily. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Maximum strength antacid contained 80 mg aluminium hydroxide, 80 mg magnesium hydroxide, and 8 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">simethicone per mL. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">This study was conducted using elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 150/150/200/10 mg once </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:243pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">daily. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on drug interaction studies conducted with Biktarvy or the components of Biktarvy, no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinically significant drug interactions are expected with: amlodipine, atorvastatin, buprenorphine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">drospirenone, famciclovir, famotidine, fluticasone, methadone, naloxone, norbuprenorphine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">omeprazole or rosuvastatin. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are no or limited data (less than 300 pregnancy outcomes) from the use of bictegravir or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tenofovir alafenamide in pregnant women.  A large amount of data on pregnant women (more than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,000 exposed outcomes) indicate no malformative nor foetal/neonatal toxicity associated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">emtricitabine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Animal studies do not indicate direct or indirect harmful effects of emtricitabine with respect to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fertility parameters, pregnancy, foetal development, parturition or postnatal development.  Studies of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bictegravir and tenofovir alafenamide, administered separately, in animals have shown no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">harmful effects on fertility parameters, pregnancy, or foetal development (see section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy should be used during pregnancy only if the potential benefit justifies the potential risk to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the foetus. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is not known whether bictegravir or tenofovir alafenamide is excreted in human milk.  Emtricitabine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is excreted in human milk.  In animal studies, bictegravir was detected in the plasma of nursing rat </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pups likely due to the presence of bictegravir in milk, without effects on nursing pups.  In animal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies it has been shown that tenofovir is excreted in milk.   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is insufficient information on the effects of all the components of Biktarvy in newborns/infants, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therefore Biktarvy should not be used during breast-feeding. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In order to avoid transmission of HIV to the infant it is recommended that women living with HIV do </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not breast-feed their infants. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No human data on the effect of Biktarvy on fertility are available.  Animal studies indicate no effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of bictegravir, emtricitabine or tenofovir alafenamide on mating or fertility (see section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">13 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy may have minor influence on the ability to drive and use machines.  Patients should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">informed that dizziness has been reported during treatment with the components of Biktarvy (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.8).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Summary of the safety profile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  In clinical studies of treatment-na&#xef;ve patients receiving Biktarvy, the most frequently reported </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions in the double-blind phase (Week 144) were headache (5%), diarrhoea (5%) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nausea (4%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tabulated list of adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The assessment of adverse reactions is based on safety data from across all Phase 2 and 3 studies with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and from post-marketing experience.  The adverse reactions in Table 2 are listed by system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">organ class and frequency.  </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Frequencies are defined as follows: common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/100 to &lt; 1/10) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">uncommon (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/1.000 to &lt; 1/100) </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and rare (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/10.000 to &lt; 1/1.000). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 2: Tabulated list of adverse reactions</span></b><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Frequency </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:189pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Adverse reaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:76pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Blood and lymphatic system disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">anaemia</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:76pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Psychiatric disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">depression, abnormal dreams </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">suicidal ideation, suicide attempt (particularly in patients with a pre-existing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">history of depression or psychiatric illness), anxiety, sleep disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:76pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Nervous system disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">headache, dizziness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:76pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Gastrointestinal disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">diarrhoea, nausea </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">vomiting, abdominal pain, dyspepsia, flatulence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:76pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Hepatobiliary disorders</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">hyperbilirubinaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:76pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Skin and subcutaneous tissue disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">angioedema</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">3,4</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">, rash, pruritus, urticaria</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">4</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Stevens-Johnson syndrome</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">5</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:76pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Musculoskeletal and connective tissue disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">arthralgia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:76pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">General disorders and administration site conditions </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:189pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">fatigue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">With the exception of angioedema, anaemia, urticaria and Stevens-Johnson syndrome (see footnotes 2-5), all adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">reactions were identified from Biktarvy clinical studies.  The frequencies were derived from the double-blind phase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">(Week 144) of Phase 3 Biktarvy clinical studies in treatment-na&#xef;ve patients (GS-US-380-1489 and GS-US-380-1490). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">This adverse reaction was not observed in the clinical studies of emtricitabine + tenofovir alafenamide-containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">products but identified from clinical studies or post-marketing experience for emtricitabine when used with other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">antiretrovirals. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">This adverse reaction was identified through post-marketing surveillance for emtricitabine-containing products. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">This adverse reaction was identified through post-marketing surveillance for tenofovir alafenamide-containing products. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">This adverse reaction was identified through post-marketing surveillance for Biktarvy. The frequency has been calculated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">using 3/X, where X represent the cumulative number of subjects exposed to Biktarvy in clinical trials (N=3963). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Description of selected adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Metabolic parameters </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4). </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">14 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immune Reactivation Syndrome</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In HIV infected patients with severe immune deficiency at the time of initiation of CART, an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inflammatory reaction to asymptomatic or residual opportunistic infections may arise.  Autoimmune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disorders (such as Graves&#x2019; disease</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and autoimmune hepatitis) have also been reported; however, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reported time to onset is more variable and these events can occur many months after initiation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Osteonecrosis</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">factors, advanced HIV disease or long-term exposure to CART.  The frequency of this is unknown </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Changes in serum creatinine </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir has been shown to increase serum creatinine due to inhibition of tubular secretion of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine, however these changes are not considered to be clinically relevant since they do not reflect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a change in glomerular filtration rate.  Increases in serum creatinine occurred by Week 4 of treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and remained stable through Week 144.  In Studies GS-US-380-1489 and GS-US-380-1490, median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Q1, Q3) serum creatinine increased by 0.11 (0.03, 0.19) mg/dL (9.7 [2.7, 16.8] &#xb5;mol/L), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.11 (0.04, 0.19) mg/dL (9.7 [3.5, 16.8] &#xb5;mol/L), and 0.12 (0.06, 0.21) mg/dL </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(10.6 [5.3, 18.6] </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x3bc;mol/L) from </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline to Week 144 in the Biktarvy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abacavir/dolutegravir/lamivudine, and dolutegravir + emtricitabine/tenofovir alafenamide groups, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">respectively.  There were no discontinuations due to renal adverse reactions through Week 144 in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients administered Biktarvy in clinical studies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Changes in bilirubin </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Studies GS-US-380-1489 and GS-US-380-1490, total bilirubin increases were observed in 17% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment-na&#xef;ve patients administered Biktarvy through Week 144.  Increases were primarily Grade 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(12%) </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and Grade 2 (4%) (&#x2265;1.0 to 2.5 x Upper Limit of Normal [ULN]), and were not associated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatic adverse reactions or other liver related laboratory abnormalities.  Five patients administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy (1%) had grade 3 bilirubin increases that were not considered related to study drug.  There </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were no discontinuations due to hepatic adverse reactions through Week 144 in Biktarvy clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety of Biktarvy was evaluated in 50 HIV-1 infected adolescents aged 12 to &lt; 18 years and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weighing &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 35 kg through Week 96 (48-week main phase and 48-week extension), in 50 children aged </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 to &lt; 12 years and </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weighing &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 25 kg through Week 96 (48-week main phase and 48-week extension), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and in 22 children </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 2 years of age and </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weighing &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 14 to &lt; 25 kg through Week 24 in an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical study (GS-US-380-1474).  In this study, no new adverse reactions have been observed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">paediatric subjects aged 2 years and older living with HIV-1 as compared to adult subjects living with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV-1.  Bone mineral density data were not collected in this study.  Reductions in BMD of the spine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and of the TBLH &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:8.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4% have been reported in paediatric patients receiving other tenofovir alafenamide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">containing products for 48</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:8.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks (see section 4.4).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Other special populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Patients co-infected with hepatitis B</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In 16 HIV/HBV co-infected adults administered Biktarvy (8 HIV/HBV treatment-na&#xef;ve adults in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Study GS-US-380-1490; 8 HIV/HBV suppressed adults in Study GS-US-380-1878), the safety profile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of Biktarvy was similar to that in patients with HIV-1 monoinfection (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies GS-US-380-1844, GS-US-380-1878 and the dedicated Study GS-US-380-4449 in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 65 years old (evaluation of 86 HIV-1 infected, virologically-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">suppressed subjects &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 65 years old) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">included 111 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients aged &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 65 years who received Biktarvy.  In these patients, no differences in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">safety profile of Biktarvy were observed.  </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">15 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Patients with renal impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety of emtricitabine + tenofovir alafenamide was evaluated in a single arm, open-label clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">study (GS-US-292-1825), in which 55 virologically-suppressed HIV-1 infected patients with end stage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal disease (eGFR</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">CG </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt; 15 mL/min) on chronic haemodialysis received emtricitabine + tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alafenamide in combination with elvitegravir + cobicistat as a fixed-dose combination tablet for 96 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks. In an extension phase of Study GS-US-292-1825, 10 patients switched to Biktarvy for 48 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weeks. No additional adverse reactions were identified in patients with end stage renal disease on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chronic haemodialysis in this study (see sections 4.4 and 5.2).</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It allows continued monitoring of the benefit/risk balance of the medicinal product.  Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">Appendix V</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If overdose occurs the patient must be monitored for evidence of toxicity (see section 4.8).  Treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of overdose with Biktarvy consists of general supportive measures including monitoring of vital signs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">as well as observation of the clinical status of the patient. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no specific antidote for overdose with Biktarvy.  As bictegravir is highly bound to plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">proteins, it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Emtricitabine can be removed by haemodialysis, which removes approximately 30% of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">emtricitabine dose over a 3-hour dialysis period starting within 1.5 hours of emtricitabine dosing.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">54%.  It is not known whether emtricitabine or tenofovir can be removed by peritoneal dialysis.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: Antiviral for systemic use; antivirals for treatment of HIV infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combinations, ATC code: J05AR20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action and pharmacodynamic effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir is an integrase strand transfer inhibitor (INSTI) that binds to the integrase active site and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blocks the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">for the HIV replication cycle.  Bictegravir has activity against HIV-1 and HIV-2. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">analogue of 2&#x2019;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-deoxycytidine.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine triphosphate.  Emtricitabine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">triphosphate inhibits HIV replication through incorporation into viral DNA by the HIV reverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">transcriptase (RT), which results in DNA chain-termination.  Emtricitabine has activity against HIV-1, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV-2 and HBV. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonamidate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">prodrug of tenofovir (2&#x2019;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-deoxyadenosine monophosphate analogue).  Tenofovir alafenamide is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">permeable into cells and due to increased plasma stability and intracellular activation through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hydrolysis by cathepsin A, tenofovir alafenamide is more efficient than tenofovir disoproxil in loading </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tenofovir into peripheral blood mononuclear cells (PBMCs) (including lymphocytes and other HIV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">target cells) and macrophages.  Intracellular tenofovir is subsequently phosphorylated to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacologically active metabolite tenofovir diphosphate.  Tenofovir diphosphate inhibits HIV </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">16 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">replication through incorporation into viral DNA by the HIV RT, which results in DNA chain-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">termination.  Tenofovir has activity against HIV-1, HIV-2 and HBV.   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Antiviral activity </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The antiviral activity of bictegravir against laboratory and clinical isolates of HIV-1 was assessed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphoblastoid cell lines, PBMCs, primary</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monocyte/macrophage cells, and CD4+ T-lymphocytes.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The 50% effective concentration (EC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) values for bictegravir were in the range of &lt; 0.05 to 6.6 nM.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The protein-adjusted EC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">95</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of bictegravir was 361 nM (0.162 &#xb5;g/mL) for wild type HIV-1 virus.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir displayed antiviral activity in cell culture against HIV-1 group (M, N, O), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subtypes A, B, C, D, E, F, and G (EC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values ranged from &lt; 0.05 to 1.71 nM), and activity against </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV-2 (EC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> = 1.1 nM). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The antiviral activity of emtricitabine against laboratory and clinical isolates of HIV-1 was assessed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphoblastoid cell lines, the MAGI CCR5 cell line, and PBMCs.  The EC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values for emtricitabine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were in the range of 0.0013 to 0.64 &#xb5;M.  Emtricitabine displayed antiviral activity in cell culture </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">against HIV-1 clades A, B, C, D, E, F, and G (EC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values ranged from 0.007 to 0.075 &#xb5;M) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">showed activity against HIV-2 (EC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values ranged from 0.007 to 1.5 &#xb5;M). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and CD4+ T-lymphocytes.  The EC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values for tenofovir alafenamide were in the range of 2.0 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">14.7 nM.  Tenofovir alafenamide displayed antiviral activity in cell culture against all HIV-1 groups </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(M, N, O), including subtypes A, B, C, D, E, F, and G (EC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values ranged from 0.10 to 12.0 nM) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">activity against HIV-2 (EC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values ranged from 0.91 to 2.63 nM). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Resistance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV-1 isolates with reduced susceptibility to bictegravir</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been selected in cell culture.  In one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">selection, amino acid substitutions M50I and R263K emerged and phenotypic susceptibility to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bictegravir was reduced 1.3-, 2.2-, and 2.9-fold for M50I, R263K, and M50I + R263K, respectively.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a second selection, amino acid substitutions T66I and S153F emerged and phenotypic susceptibility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to bictegravir</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was shifted 0.4-, 1.9-, and 0.5-fold for T66I, S153F, and T66I + S153F, respectively. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV-1 isolates with reduced susceptibility to emtricitabine</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been selected in cell culture and had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">M184V/I mutations in HIV-1 RT. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV-1 isolates with reduced susceptibility to tenofovir alafenamide have been selected in cell culture </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and had the K65R mutation in HIV-1 RT; in addition, a K70E mutation in HIV-1 RT has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">transiently observed.  HIV-1 isolates with the K65R mutation have low level reduced susceptibility to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abacavir, emtricitabine, tenofovir, and lamivudine.  </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> drug resistance selection studies with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tenofovir alafenamide have shown no development of high-level resistance after extended culture. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In treatment-na&#xef;ve patients (Studies GS-US-380-1489 and GS-US-380-1490), through Week 144 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the double-blind phase or 96 weeks of the open-label extension phase, no patient receiving Biktarvy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with HIV-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 RNA &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 200 copies/mL at the time of confirmed virologic failure or early study drug </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">discontinuation, had HIV-1 with treatment-emergent genotypic or phenotypic resistance to bictegravir, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">emtricitabine, or tenofovir alafenamide in the final resistance analysis population (n = 11 with data).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At the time of study entry, one treatment-na&#xef;ve patient had pre-existing INSTI resistance-associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mutations Q148H + G140S and had HIV-1 RNA &lt; 50 copies/mL at Week 4 through Week 144. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">addition, 6 patients had the pre-existing INSTI resistance-associated mutation T97A; all had HIV-1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">RNA &lt; 50 copies/mL at Week 144 or the last visit. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In virologically-suppressed patients (Studies GS-US-380-1844 and GS-US-380-1878), no patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receiving Biktarvy, with HIV-1 RNA </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 200 copies/mL at the time of confirmed virologic failure, </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">17 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 48, or early study drug discontinuation, had HIV-1 with treatment-emergent genotypic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">phenotypic resistance to bictegravir, emtricitabine, or tenofovir alafenamide in the final resistance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">analysis population (n = 2).</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:12pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Cross-resistance  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The susceptibility of bictegravir was tested against 64 INSTI-resistant clinical isolates (20 with single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">substitutions and 44 with 2 or more substitutions).  Of these, all single and double mutant isolates </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lacking Q148H/K/R and 10 of 24 isolates with Q148H/K/R with additional INSTI resistance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">associated substitutions had &#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 2.5-fold reduced susceptibility to bictegravir; &gt; 2.5-fold reduced </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">susceptibility to bictegravir was found for 14 of the 24 isolates that contained G140A/C/S and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Q148H/R/K substitutions in integrase.  Of those, 9 of the 14 isolates had additional mutations at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">L74M, T97A, or E138A/K.  In a separate study, site-directed mutants with G118R and T97A+G118R </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">had 3.4- and 2.8-fold reduced susceptibility to bictegravir, respectively.  The relevance of these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> cross-resistance data remains to be established in clinical practice. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir demonstrated equivalent antiviral activity against 5 nonnucleoside reverse transcriptase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitor (NNRTI)-resistant, 3 NRTI-resistant, and 4 protease inhibitor (PI)-resistant HIV-1 mutant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clones compared with the wild-type strain. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Emtricitabine-resistant viruses with the M184V/I substitution were cross-resistant to lamivudine, but </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">retained sensitivity to didanosine, stavudine, tenofovir, and zidovudine.   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The K65R and K70E mutations result in reduced susceptibility to abacavir, didanosine, lamivudine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">emtricitabine, and tenofovir, but retain sensitivity to zidovudine.  Multinucleoside resistant HIV-1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with a T69S double insertion mutation or with a Q151M mutation complex including K65R showed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduced susceptibility to tenofovir alafenamide.   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical data </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy and safety of Biktarvy in HIV-1 infected, treatment-na&#xef;ve adults are based on 48-week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 144-week data from two randomised, double-blind, active-controlled studies, GS-US-380-1489 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(n = 629) and GS-US-380-1490 (n = 645).  Furthermore, additional efficacy and safety data are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available from adults who received open-label Biktarvy for an additional 96 weeks after Week 144 in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">an optional extension phase of these studies (n = 1025). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy and safety of Biktarvy in virologically-suppressed HIV-1 infected adults are based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">48-week data from a randomised, double-blind, active-controlled study, GS-US-380-1844 (n = 563); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and a randomised, open-label, active-controlled study, GS-US-380-1878 (n = 577). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">HIV-1 infected, treatment-na&#xef;ve patients </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Study GS-US-380-1489, patients were randomised in a 1:1 ratio to receive either </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (n = 314) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abacavir/dolutegravir/lamivudine (600/50/300 mg) (n = 315) once daily.  In Study GS-US-380-1490, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients were randomised in a 1:1 ratio to receive either B/F/TAF (n = 320) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir + emtricitabine/tenofovir alafenamide (50+200/25 mg) (n = 325) once daily. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Studies GS-US-380-1489 and GS-US-380-1490, the mean age was 35 years (range 18-77), 89% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were male, 58% were White, 33% were Black, and 3% were Asian.  Twenty-four percent (24%) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients identified as Hispanic/Latino.  The prevalence of different subtypes was comparable across all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">three treatment groups, with subtype B predominant in both groups; 11% were non-B subtypes.  The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mean baseline plasma HIV-1 RNA was 4.4 log</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">10</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> copies/mL (range 1.3-6.6).  The mean baseline CD4+ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cell count was 460 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> (range 0-1,636) and 11% had CD4+ cell counts less than 200 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Eighteen percent of patients had baseline viral loads greater than 100,000 copies/mL.  In both studies, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients were stratified by baseline HIV-1 RNA (less than or equal to 100,000 copies/mL, greater than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100,000 copies/mL to less than or equal to 400,000 copies/mL, or greater than 400,000 copies/mL), by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CD4+ cell count (less than 50 cells/&#xb5;L, 50-199 cells/&#xb5;L, or greater than or equal to 200 cells/&#xb5;L), and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">by region (US or ex-US). </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">18 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Treatment outcomes of Studies GS-US-380-1489 and GS-US-380-1490 through Weeks 48 and 144 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are presented in Table 3. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 3: Pooled virologic outcomes of Studies GS-US-380-1489 and GS-US-380-1490 at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Weeks 48</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt">a </span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">and 144</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt">b</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:246pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Week 48  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:428pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Week 144  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:184pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">B/F/TAF </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:183pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(n = 634)</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">c</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:240pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">ABC/DTG/</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:255pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">3TC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:244pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(n = 315)</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">d</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:311pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">DTG + </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:312pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">F/TAF </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:306pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(n = 325)</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">e</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:368pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">B/F/TAF </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:367pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(n = 634)</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">c</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:425pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">ABC/DTG/</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:439pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">3TC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:428pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(n = 315)</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">d</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:495pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">DTG + </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:496pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">F/TAF </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:490pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(n = 325)</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">e</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">HIV-1 RNA </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">&lt; 50 copies/mL  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:194pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">91% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:255pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">93% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:317pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">93% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">82% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">84% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:501pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">84% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">difference </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(95% CI) B/F/TAF </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">vs Comparator </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:202pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:253pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-2.1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:246pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(-5.9% to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:253pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1.6%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:314pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-1.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:307pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(-5.6% to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:314pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1.8%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:388pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:386pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">- </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:437pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-2.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:430pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(-7.8% to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:437pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2.4%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:498pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-1.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:491pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(-7.0% to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:498pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3.1%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">HIV-1 RNA </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">&#x2265;</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> 50 copies/mL</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">f</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:196pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:258pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:319pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:381pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:442pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:504pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">No virologic data at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">week 48 or 144 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">window </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:196pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:258pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:319pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">16% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">13% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:501pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">13% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Discontinued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">study drug due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AE or death</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">g</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:194pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:258pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:319pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:381pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:442pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:504pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Discontinued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">study drug due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">other reasons and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">last available HIV-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1 RNA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&lt; 50 copies/mL</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">h</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:196pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:258pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:319pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">13% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">11% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:504pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Missing data </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">during window but </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">on study drug </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:196pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:255pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:319pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:381pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:439pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:504pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Proportion (%) of </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">patients with </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">HIV-1 RNA </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">&lt; 50 copies/mL by </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">subgroup</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:203pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:265pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:326pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:388pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:510pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">By baseline viral load </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 100,000 copies/</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">mL </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&gt; 100,000 copies/</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">mL </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:203pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:194pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">92% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:194pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">87% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:265pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:255pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">94% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:255pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">90% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:326pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:317pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">93% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:317pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">94% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:388pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">82% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">79% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">86% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">74% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:510pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:501pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">84% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:501pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">83% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">By baseline CD4+ cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">count </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&lt; 200 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> 200 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:203pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:194pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">90% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:194pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">91% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:265pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:255pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">81% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:255pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">94% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:326pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:314pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">100% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:317pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">92% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:388pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">80% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">82% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">69% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">86% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:510pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:501pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">91% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:501pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">83% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">HIV-1 RNA </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">&lt; 20 copies/mL </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:194pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">85% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:255pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">87% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:317pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">87% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">78% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">82% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:501pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">79% </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">19 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">ABC = abacavir</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:156pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">DTG = dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:241pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">3TC = lamivudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:326pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">F/TAF = emtricitabine/tenofovir alafenamide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:66pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:66pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Week 48 window was between Day 295 and 378 (inclusive). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">b </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Week 144 window was between Day 967 and 1050 (inclusive). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:86pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">c </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:86pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Pooled from Study GS-US-380-1489 (n = 314) and Study GS-US-380-1490 (n = 320). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">d </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Study GS-US-380-1489. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">e </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Study GS-US-380-1490. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">f </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Includes patients who had &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt"> 50 copies/mL in the Week 48 or 144 window; patients who discontinued early due to lack or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:128pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">loss of efficacy (n = 0); patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">efficacy (B/F/TAF n = 12 and 15; ABC/DTG/3TC n = 2 and 7; DTG+F/TAF n = 3 and 6, at Weeks 48 and 144, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">respectively) and at the time of discontinuation had a </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">viral value of &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt"> 50 copies/mL. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">g </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">resulted in no virologic data on treatment during the specified window. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">h </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy, e.g. withdrew consent, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">loss to follow-up, etc. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">B/F/TAF was non-inferior in achieving HIV-1 RNA &lt; 50 copies/mL at both Weeks 48 and 144 when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to abacavir/dolutegravir/lamivudine and to dolutegravir + emtricitabine/tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alafenamide, respectively.  Treatment outcomes between treatment groups were similar across </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subgroups by age, sex, race, baseline viral load, baseline CD4+ cell count, and region. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Studies GS-US-380-1489 and GS-US-380-1490, the mean increase from baseline in CD4+ cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">count at Week 144 was 288, 317, and 289 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in the pooled B/F/TAF, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abacavir/dolutegravir/lamivudine, and dolutegravir + emtricitabine/tenofovir alafenamide groups, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">respectively. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the optional 96 week open-label extension phase of Studies GS-US-380-1489 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and GS-US-380-1490, high rates of virologic suppression were achieved and maintained. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">HIV-1 infected, virologically -suppressed patients </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Study GS-US-380-1844, the efficacy and safety of switching from a regimen of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir + abacavir/lamivudine or abacavir/dolutegravir/lamivudine to B/F/TAF were evaluated in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a randomised, double-blind study of virologically-suppressed (HIV-1 RNA &lt; 50 copies/mL) HIV-1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infected adults (n = 563).  Patients must have been stably suppressed (HIV-1 RNA &lt; 50 copies/mL) on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">their baseline regimen for at least 3 months prior to study entry.  Patients were randomised in a 1:1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ratio to either switch to B/F/TAF at baseline (n = 282), or stay on their baseline antiretroviral regimen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(n = 281).  Patients had a mean age of 45 years (range 20-71), 89% were male, 73% were White, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">22% were Black.  Seventeen percent (17%) of patients identified as Hispanic/Latino.  The prevalence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of different HIV-1 subtypes was comparable between treatment groups, with subtype B predominant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in both groups; 5% were non-B subtypes.  The mean baseline CD4+ cell count was 723 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(range 124-2,444).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Study GS-US-380-1878, the efficacy and safety of switching from either abacavir/lamivudine or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">emtricitabine/tenofovir disoproxil fumarate (200/300 mg) plus atazanavir or darunavir (boosted by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">either cobicistat or ritonavir) to B/F/TAF were evaluated in a randomised, open-label study of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">virologically-suppressed HIV-1 infected adults (n = 577).  Patients must have been stably suppressed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">on their baseline regimen for at least 6 months and must not have been previously treated with any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">INSTI.  Patients were randomised in a 1:1 ratio to either switch to B/F/TAF (n = 290), or stay on their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline antiretroviral regimen (n = 287).  Patients had a mean age of 46 years (range 20-79), 83% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were male, 66% were White, and 26% were Black.  Nineteen percent (19%) of patients identified as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hispanic/Latino.  The mean baseline CD4+ cell count was 663 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> (range 62-2,582).  The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">prevalence of different subtypes was comparable across treatment groups, with subtype B predominant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in both groups; 11% were non-B subtypes.  Patients were stratified by prior treatment regimen.  At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">screening, 15% of patients were receiving abacavir/lamivudine plus atazanavir or darunavir (boosted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">by either cobicistat or ritonavir) and 85% of patients were receiving emtricitabine/tenofovir disoproxil </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fumarate plus atazanavir or darunavir (boosted by either cobicistat or ritonavir).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:731pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Treatment outcomes of Studies GS-US-380-1844 and GS-US-380-1878 through Week 48 are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:744pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">presented in Table 4. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:756pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 4: Virologic outcomes of Studies GS-US-380-1844 and GS-US-380-1878 at Week 48</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt">a </span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:261pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Study GS-US-380-1844</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:412pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Study GS-US-380-1878</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:248pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">B/F/TAF </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:116pt;left:248pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(n = 282)</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:312pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">ABC/DTG/3TC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:116pt;left:326pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(n = 281)</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:401pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">B/F/TAF </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:116pt;left:401pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(n = 290)</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:462pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Baseline ATV- </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:106pt;left:463pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">or DRV-based </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:476pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">regimen </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:474pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(n = 287)</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">HIV-1 RNA &lt; 50 copies/mL </span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:258pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">94%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:336pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">95%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:411pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">92%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:484pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">89%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Treatment difference (95% CI)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:264pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-1.4% (-5.5% to 2.6%)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:418pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3.2% (-1.6% to 8.2%)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">HIV-1 </span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">RNA &#x2265;</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> 50 copies/mL</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">b</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:261pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:335pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&lt; 1%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:413pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:487pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Treatment difference (95% CI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:266pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.7% (-1.0% to 2.8%)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:418pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.0% (-2.5% to 2.5%)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">No virologic data at Week 48 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">window</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:261pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">5%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">5%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:413pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">6%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:487pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">9%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Discontinued study drug due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AE or death and last available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">HIV-1 RNA &lt; 50 copies/mL</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:261pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:413pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:487pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Discontinued study drug due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">other reasons and last available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">HIV-1 RNA &lt; 50 copies/mL</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">c</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:261pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:413pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:487pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">7%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Missing data during window but </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:90pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">on study drug</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:261pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:413pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:487pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">ABC = abacavir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:156pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">ATV = atazanavir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:241pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">DRV = darunavir</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:326pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">DTG </span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9pt">= </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:411pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">3TC = lamivudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Week 48 window was between Day 295 and 378 (inclusive). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">b </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Includes patients who had &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt"> 50 copies/mL in the Week 48 window; patients who discontinued early due to lack or loss of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">efficacy; patients who discontinued for reasons other than lack or loss of efficacy and at the time of discontinuation had a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">viral value of &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt"> 50 copies/mL. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">c </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy, e.g. withdrew consent, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">loss to follow-up, etc. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">B/F/TAF was non-inferior to the control regimen in both studies.  Treatment outcomes between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment groups were similar across subgroups by age, sex, race, and region. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In GS-US-380-1844, the mean change from baseline in CD4+ cell count at Week 48 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was -31 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in patients who switched to B/F/TAF and 4 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in patients who stayed on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abacavir/dolutegravir/lamivudine.  In GS-US-380-1878, the mean change from baseline in CD4+ cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">count at Week 48 was 25 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in patients who switched to B/F/TAF and 0 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">who stayed on their baseline regimen. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Patients co-infected with HIV and HBV </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The number of patients co-infected with HIV and HBV treated with B/F/TAF is limited.  In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Study GS-US-380-1490, 8 patients with HIV/HBV co-infection at baseline were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">receive B/F/TAF. At Week 48, 7 patients were HBV suppressed (HBV DNA &lt; 29 IU/mL) and had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV-1 RNA &lt; 50 copies/mL.  One patient had missing HBV DNA data at Week 48.  At Week 144, 5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients were HBV suppressed and had HIV-1 RNA &lt; 50 copies/mL.  Three patients had missing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HBV DNA data at Week 144 (1 lost to follow-up from Week 48, 1 lost to follow-up after Week 72, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 1 lost to follow-up after Week 120). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Study GS-US-380-1878, at Week 48, 100% (8/8) of the patients co-infected with HIV/HBV at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">baseline in the B/F/TAF arm maintained HBV DNA &lt; 29 IU/mL (missing = excluded analysis) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV RNA &lt; 50 copies/mL. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In Study GS-US-380-1474, the pharmacokinetics, safety and efficacy of B/F/TAF in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">virologically-suppressed children and adolescents with HIV between the ages of 12 to &lt; 18 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 35 kg) (n = 50), between the ages of 6 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12 years (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 25 kg) (n = </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50), and &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 years of age (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 14 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:734pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to &lt; 25 kg) (n = 22) were evaluated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cohort 1: Virologically-suppressed adolescents (n = 50; 12 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">18 years; &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 35 kg)  </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">21 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients in Cohort 1 had a mean age of 14 years (range: 12 to 17) and a mean baseline weight of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">51.7 kg (range: 35 to 123), 64% were female, 27% were Asian, and 65% were Black.  At baseline, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">median CD4+ cell count was 750 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> (range: 337 to 1207), and median CD4+% was 33% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(range: 19% to 45%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After switching to B/F/TAF, 98% (49/50) of patients in Cohort 1 remained suppressed (HIV-1 RNA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt; 50 copies/mL) at Week 48.  The mean change from baseline in CD4+ cell count at Week 48 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was -22 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">.  Two of 50 subjects met the criteria for inclusion in the resistance analysis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">population through Week 48.  No emergent resistance to B/F/TAF was detected through Week 48. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cohort 2: Virologically-suppressed children (n = 50; 6 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12 years; &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 25 kg)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients in Cohort 2 had a mean age of 10 years (range: 6 to 11) and a mean baseline weight of 31.9 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(range: 25 to 69), 54% were female, 22% were Asian and 72% were Black.  At baseline, median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CD4+ cell count was 898 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> (range 390 to 1991) and median CD4+% was 37% (range: 19% to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">53%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After switching to B/F/TAF, 98% (49/50) of patients in Cohort 2 remained suppressed (HIV-1 RNA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt; 50 copies/mL) at Week 48.  The mean change from baseline in CD4+ cell count at Week 48 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was -40 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">.  No patient qualified for resistance analysis through Week 48. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cohort 3: Virologically-suppressed children (n = </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">22; &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 years; &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 14 kg to &lt; 25 kg)  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients in Cohort 3 had a mean age of 5 years (range: 3 to 9) and a mean baseline weight of 18.8 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(range: 14 to 24), 50% were female, 23% were Asian and 73% were Black.  At baseline, median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CD4+ cell count was 962 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> (range 365 to 1986) and median CD4+% was 32% (range: 24% to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">46%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After switching to B/F/TAF, 91% (20/22) of patients in Cohort 3 remained suppressed (HIV-1 RNA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt; 50 copies/mL) at Week 24.  The mean change from baseline in CD4+ cell count at Week 24 was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2212;126 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, and the mean change in CD4+% from baseline to Week 24 was 0.2% (range: -7.7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to 7.5%).  No patient qualified for resistance analysis through Week 24. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The European Medicines Agency has deferred the obligation to submit the results of studies with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy in one or more subsets of the paediatric population in the treatment of human </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV-1 infection (see section 4.2 for information on paediatric use). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absorption </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir is absorbed following oral administration with peak plasma concentrations occurring at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.0-4.0 hours after administration of B/F/TAF.  Relative to fasting conditions, the administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">B/F/TAF with either a moderate fat (~600 kcal, 27% fat) or high fat meal (~800 kcal, 50% fat) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">resulted in an increase in bictegravir AUC (24%).  This modest change is not considered clinically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">meaningful and B/F/TAF can be administered with or without food. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Following oral administration of B/F/TAF with or without food in HIV-1 infected adults, the multiple </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose mean (CV%) pharmacokinetic parameters of bictegravir were C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> = 6.15 &#xb5;g/mL (22.9%), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">tau</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> = 102 &#xb5;g</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2022;h</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/mL (26.9%), and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">trough</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> = 2.61 &#xb5;g/mL (35.2%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentrations occurring at 1.5-2.0 hours after administration of B/F/TAF.  The mean absolute </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bioavailability of emtricitabine from 200 mg hard capsules was 93%.  Emtricitabine systemic exposure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was unaffected when emtricitabine was administered with food and B/F/TAF can be administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or without food. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">22 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Following oral administration of B/F/TAF with or without food in HIV-1 infected adults, the multiple </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose mean (CV%) pharmacokinetic parameters of emtricitabine were C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> = 2.13 &#xb5;g/mL (34.7%), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">tau</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> = 12.3 &#xb5;g</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2022;h</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/mL (29.2%), and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">trough</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> = 0.096 &#xb5;g/mL (37.4%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tenofovir alafenamide is rapidly absorbed following oral administration with peak plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentrations occurring at 0.5-2.0 hours after administration of B/F/TAF.  Relative to fasting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">conditions, the administration of tenofovir alafenamide with a moderate fat meal (~600 kcal, 27% fat) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and a high fat meal (~800 kcal, 50% fat) resulted in an increase in AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">last</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> by 48% and 63%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">respectively.  These modest changes are not considered clinically meaningful and B/F/TAF can be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administered with or without food.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Following oral administration of B/F/TAF with or without food in HIV-1 infected adults, the multiple </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose mean (CV%) pharmacokinetic parameters of tenofovir alafenamide were C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> = 0.121 &#xb5;g/mL </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(15.4%), and AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">tau</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> = 0.142 &#xb5;g</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2022;h</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/mL (17.3%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Distribution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> binding of bictegravir</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to human plasma proteins was &gt; 99% (free fraction ~0.25%).  The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> human blood to plasma bictegravir</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentration ratio was 0.64. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> binding of emtricitabine to human plasma proteins was &lt; 4% and independent of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentration over the range of 0.02 to 200 &#xb5;g/mL.  At peak plasma concentration, the mean plasma to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood emtricitabine concentration ratio was ~1.0 and the mean semen to plasma emtricitabine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentration ratio was ~4.0. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> binding of tenofovir to human plasma proteins is &lt; 0.7% and is independent of concentration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">over the range of 0.01-25 &#xb5;g/mL.  </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Ex vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> binding of tenofovir alafenamide to human plasma proteins </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in samples collected during clinical studies was approximately 80%.   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biotransformation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metabolism is the major clearance pathway for bictegravir in humans.  </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> phenotyping studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">showed that bictegravir is primarily metabolised by CYP3A and UGT1A1.  Following a single dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oral administration of [</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C]-bictegravir, ~60% of the dose from faeces included unchanged parent, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">desfluoro-hydroxy-BIC-cysteine-conjugate, and other minor oxidative metabolites.  Thirty-five </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">percent of the dose was recovered from urine and consisted primarily of the glucuronide of bictegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and other minor oxidative metabolites and their phase II conjugates.  Renal clearance of the unchanged </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">parent was minimal. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Following administration of [</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C]-emtricitabine, complete recovery of the emtricitabine dose was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">achieved in urine (~86%) and faeces (~14%).  Thirteen percent of the dose was recovered in the urine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">as three putative metabolites.  The biotransformation of emtricitabine includes oxidation of the thiol </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">moiety to form the 3&#x2019;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-sulfoxide diastereomers (~9% of dose) and conjugation with glucuronic acid to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">form 2&#x2019;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-O-glucuronide (~4% of dose).  No other metabolites were identifiable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metabolism is a major elimination pathway for tenofovir alafenamide in humans, accounting for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&gt; 80% of an oral dose.  </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> studies have shown that tenofovir alafenamide is metabolised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tenofovir (major metabolite) by cathepsin A in PBMCs (including lymphocytes and other HIV target </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cells) and macrophages; and by carboxylesterase-1 in hepatocytes.  </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, tenofovir alafenamide is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hydrolysed within cells to form tenofovir (major metabolite), which is phosphorylated to the active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolite, tenofovir diphosphate.  In human clinical studies, a 25 mg oral dose of tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alafenamide resulted in tenofovir diphosphate concentrations &gt; 4-fold higher in PBMCs and &gt; 90% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">23 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elimination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir is primarily eliminated by hepatic metabolism.  Renal excretion of intact bictegravir is a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">minor pathway (~1% of dose).  The plasma bictegravir half-life was 17.3 hours.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Emtricitabine is primarily excreted by the kidneys by both glomerular filtration and active tubular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">secretion.  The plasma emtricitabine half-life was approximately 10 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tenofovir alafenamide is eliminated following metabolism to tenofovir.  Tenofovir alafenamide and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tenofovir have a median plasma half-life of 0.51 and 32.37 hours, respectively.  Tenofovir is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">eliminated by the kidneys by both glomerular filtration and active tubular secretion.  Renal excretion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of intact tenofovir alafenamide is a minor pathway with less than 1% of the dose eliminated in urine.   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Linearity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The multiple dose pharmacokinetics of bictegravir are dose proportional over the dose range of 25 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 mg.  The multiple dose pharmacokinetics of emtricitabine are dose proportional over the dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">range of 25 to 200 mg.  Tenofovir alafenamide exposures are dose proportional over the dose range of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8 mg to 125 mg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Other special populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinically relevant changes in the pharmacokinetics of bictegravir were not observed in subjects with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">moderate hepatic impairment.  The pharmacokinetics of emtricitabine have not been studied in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subjects with hepatic impairment; however, emtricitabine is not significantly metabolised by liver </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">enzymes, so the impact of liver impairment should be limited.  Clinically relevant changes in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacokinetics of tenofovir alafenamide or its metabolite tenofovir were not observed in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with mild, moderate, or severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment: </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Severe Renal Impairment (estimated creatinine clearance &#x2265; 15 and &lt; 30 mL/minute)</span></i><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No clinically relevant differences in bictegravir, tenofovir alafenamide, or tenofovir pharmacokinetics </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were observed between healthy subjects and subjects with severe renal impairment (estimated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CrCl </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 15 mL/min and &lt; 30 mL/min) in Phase 1 Studies.  In a separate Phase 1 study of emtricitabine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alone, mean systemic emtricitabine exposure was higher in patients with severe renal impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(CrCl &lt; 30 mL/min) (33.7 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#xb5;g&#x2022;h/mL) than in subjects with normal renal function (11.8</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#xb5;g&#x2022;h/mL).  The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">safety of Biktarvy has not been established in subjects with estimated creatinine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clearance </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 15 mL/min and &lt; 30 mL/min. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">End Stage Renal Disease (estimated creatinine clearance &lt; 15 mL/minute) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Exposures of emtricitabine and tenofovir in 12 patients with end stage renal disease (estimated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CrCl &lt; 15 mL/min) on chronic haemodialysis who received emtricitabine + tenofovir alafenamide in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combination with elvitegravir + cobicistat as a fixed dose combination tablet in Study GS-US-292-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1825 were significantly higher than in patients with normal renal function.  No clinically relevant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">differences in tenofovir alafenamide pharmacokinetics were observed in patients with end stage renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease on chronic haemodialysis as compared to those with normal renal function.  In the extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">phase of Study GS-US-292-1825, lower bictegravir C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">trough</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was observed in patients with end stage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal disease who received Biktarvy compared to patients with normal renal function, but this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">difference was not considered clinically relevant.  No additional adverse reactions were identified in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with end stage renal disease on chronic haemodialysis in this study (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are no pharmacokinetic data on bictegravir, emtricitabine or tenofovir alafenamide in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with end stage renal disease (estimated CrCl &lt; 15 mL/min) not on chronic haemodialysis.  The safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of Biktarvy has not been established in these patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Age, gender and race </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacokinetics of bictegravir, emtricitabine, and tenofovir have not been fully evaluated in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">elderly (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 65 years of age).  Population analyses using pooled pharmacokinetic data from adult studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">did not identify any clinically relevant differences due to age, gender or race on the exposures of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">bictegravir, emtricitabine, or tenofovir alafenamide. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mean bictegravir C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, and exposures of emtricitabine and tenofovir alafenamide (AUC and/or C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">achieved in 50 children between the ages of 6 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12 years (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 25 kg) who received the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50 mg/200 mg/25 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mg dose of B/F/TAF and in 22 children &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 years of age (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 14 to &lt; 25 kg) who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">received the 30 mg/120 mg/15 mg dose of B/F/TAF, in Study GS-US-380-1474 were generally higher </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">than exposures in adults.  The exposures of bictegravir, emtricitabine, tenofovir alafenamide and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tenofovir in children, adolescents, and adults are presented in Table 5. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 5: Exposures of Bictegravir, Emtricitabine, Tenofovir Alafenamide and Tenofovir in </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Children, Adolescents, and Adults </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:164pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Children aged &#x2265;</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> 2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:191pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">years </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:170pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">&#x2265;</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> 14 to &lt; 25 kg</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">a</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:266pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Children aged 6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:273pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">to &lt; 12 years </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:283pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">&#x2265; 25</span></b><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> kg</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">a</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:353pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Adolescents aged </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:357pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">12 to &lt; 18 years </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:373pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">&#x2265; 35 kg</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">a</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:463pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Adults</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.48pt">b</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:440pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:76pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:183pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">B/F/TAF </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:155pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(30 mg/120 mg/15 mg) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:370pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">B/F/TAF  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:342pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">(50 mg/200 mg/25 mg) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:190pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">n = 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:287pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">n = 25 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:377pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">n = 24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:466pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">n = 77 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">BIC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:155pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:261pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:350pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:440pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">tau</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(ng&#x2022;h/mL)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:169pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">108 364.5 (22.9) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:267pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">121 034.2 (36.4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:357pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">109 668.1 (30.6) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">94 227.1 (34.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(ng/mL) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:172pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">10 040.0 (19.9) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:269pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">10 988.8 (28.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:362pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">8 087.1 (29.9) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">6 801.6 (30.1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">tau</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(ng/mL) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:173pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1 924.5 (78.3)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">c</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:270pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2 366.6 (78.8)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">d</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:362pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2 327.4 (48.6) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:449pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2 256.7 (47.3)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">g</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">FTC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:203pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:479pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">tau</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(ng&#x2022;h/mL)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:172pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">14 991.2 (21.9) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:269pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">17 565.1 (36.9) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:359pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">13 579.1 (21.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:448pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">12 293.6 (29.2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(ng/mL) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:174pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3 849.2 (34.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:272pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">3 888.4 (31.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:362pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2 689.2 (34.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:451pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">2 127.0 (34.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">tau</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(ng/mL) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:174pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">210.3 (242.9)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">c</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:271pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">226.7 (322.8)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">d</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:368pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">64.4 (25.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:456pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">96.0 (37.4)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">h</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">TAF </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:203pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:479pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">tau</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(ng&#x2022;h/mL)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:178pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">305.4 (42.6) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:274pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">434.5 (94.9)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">e</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:362pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">347.9 (113.2)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">f</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:455pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">229.3 (63.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(ng/mL) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:178pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">413.8 (31.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:274pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">581.8 (99.9)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">d</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:363pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">333.9 (110.6) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:455pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">276.5 (62.4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">tau</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(ng/mL) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:194pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:381pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:471pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N/A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:76pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">TFV </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:203pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:300pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:390pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:479pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">tau</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(ng&#x2022;h/mL)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:178pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">326.6 (23.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:276pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">427.7 (28.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:365pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">333.5 (31.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:454pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">292.6 (27.4)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">i</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(ng/mL) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:181pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">21.9 (29.2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:278pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">35.5 (89.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:368pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">24.0 (64.2) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:456pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">15.2 (26.1)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">i</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">tau</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:84pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(ng/mL) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:179pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">10.3 (30.5)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">c</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:276pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">14.0 (30.2)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">d</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:368pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">11.1 (32.4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:456pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">10.6 (28.5)</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">i</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">BIC = bictegravir; FTC = emtricitabine; TAF = tenofovir alafenamide fumarate; TFV = tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">N/A = not applicable; %CV = percentage coefficient of variation</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9pt"> </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">25 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Data are presented as mean (%CV). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:65pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">a</span><span style="font-family:ArialMT,sans-serif;font-size:9pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:66pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Intensive PK data from Study GS-US-380-1474 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:76pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">b</span><span style="font-family:ArialMT,sans-serif;font-size:9pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Intensive PK data from Studies GS-US-380-1489, GS-US-380-1490, GS-US-380-1844, GS-US-380-1878 for BIC, FTC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:86pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">and TAF PK exposures and population PK data from Studies GS-US-292-0104 and GS-US-292-0111 for TFV PK </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">exposures </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">c</span><span style="font-family:ArialMT,sans-serif;font-size:9pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">n = 11  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">d</span><span style="font-family:ArialMT,sans-serif;font-size:9pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">n = 24  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">e</span><span style="font-family:ArialMT,sans-serif;font-size:9pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:128pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">n = 22  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">f</span><span style="font-family:ArialMT,sans-serif;font-size:9pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">n = 23 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">g</span><span style="font-family:ArialMT,sans-serif;font-size:9pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">n = 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">h</span><span style="font-family:ArialMT,sans-serif;font-size:9pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">n = 74  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">i</span><span style="font-family:ArialMT,sans-serif;font-size:9pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:85pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">n = 841 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir was not mutagenic or clastogenic in conventional genotoxicity assays. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bictegravir was not carcinogenic in a 6-month rasH2 transgenic mouse study (at doses of up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 mg/kg/day in males and 300 mg/kg/day in females, which resulted in exposures of approximately </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15 and 23 times, in males and females, respectively, the exposure in humans at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">human dose) nor in a 2-year rat study (at doses of up to 300 mg/kg/day, which resulted in exposures of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">approximately 31 times the exposure in humans).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies of bictegravir in monkeys revealed the liver as the primary target organ of toxicity.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatobiliary toxicity was described in a 39-week study at a dosage of 1,000 mg/kg/day, which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">resulted in exposures of approximately 16 times the exposure in humans at the recommended human </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose, and was partially reversible after a 4-week recovery period.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies in animals with bictegravir have shown no evidence of teratogenicity or an effect on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reproductive function.  In offspring from rat and rabbit dams treated with bictegravir during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy, there were no toxicologically significant effects on developmental endpoints. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Non-clinical data on emtricitabine reveal no special hazard for humans based on conventional studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reproduction and development.  Emtricitabine has demonstrated low carcinogenic potential in mice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and rats. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Non-clinical studies of tenofovir alafenamide in rats and dogs revealed bone and kidney as the primary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">target organs of toxicity.  Bone toxicity was observed as reduced bone mineral density in rats and dogs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at tenofovir exposures at least 43 times greater than those expected after administration of B/F/TAF.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tenofovir exposures of approximately 14 and 43 times greater, respectively, than those expected after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of B/F/TAF. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tenofovir alafenamide was not mutagenic or clastogenic in conventional genotoxicity assays. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Because there is a lower tenofovir exposure in rats and mice after the administration of tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alafenamide compared to tenofovir disoproxil, carcinogenicity studies and a rat peri-postnatal study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were conducted only with tenofovir disoproxil.  No special hazard for humans was revealed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">conventional studies of carcinogenic potential and toxicity to reproduction and development.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">foetal parameters.  However, tenofovir disoproxil reduced the viability index and weight of pups in a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">peri-postnatal toxicity study at maternally toxic doses. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">26 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tablet core </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Microcrystalline cellulose (E460) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Croscarmellose sodium (E468) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Magnesium stearate (E470b) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Film-coating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Polyvinyl alcohol (E203) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Titanium dioxide (E171) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Macrogol (E1521) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Talc (E553b) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Iron oxide red (E172) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Iron oxide black (E172) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not applicable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bottle </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blister </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bottle </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Store in the original package in order to protect from moisture.  Keep the bottle tightly closed.  Do not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use if seal over bottle opening is broken or missing. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blister </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Store in the original package in order to protect from moisture.  Do not use if foil over blister is broken </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or pierced. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following pack configurations are available: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Bottle </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy 30 mg/120 mg/15 mg tablets and 50 mg/200 mg/25 mg tablets are packaged in white, high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">density polyethylene (HDPE) bottle with a polypropylene continuous-thread, child-resistant cap, lined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with an induction activated aluminium foil liner containing 30 film-coated tablets.  Each bottle </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contains silica gel desiccant and polyester coil. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:127pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Outer carton containing 1 bottle of 30 film-coated tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:127pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Outer carton containing 90 (3 bottles of 30) film-coated tablets. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blister </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:725pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biktarvy 50 mg/200 mg/25 mg blister packs consisting of polyvinyl </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chloride/polyethylene/polychlorotrifluoroethylene (PVC/PE/PCTFE) film, sealed to aluminium foil </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:751pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lidding material fitted with a molecular sieve desiccant within each blister cavity.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:763pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:35pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:794pt;left:284pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">27 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:54pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:55pt;left:127pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Outer carton containing 30 film-coated tablets (4 x blister strips containing 7 film-coated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:67pt;left:127pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tablets and 1 x blister strip containing 2 film-coated tablets). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:127pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Outer carton containing 90 (3 blister packs of 30) film-coated tablets. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:93pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:105pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gilead Sciences Ireland UC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Carrigtohill </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">County Cork, T45 DP77 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ireland </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER(S) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/18/1289/001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/18/1289/002 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/18/1289/003 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/18/1289/004 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/18/1289/005 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/18/1289/006 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 21 June 2018 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency http://www.ema.europa.eu. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:214pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>




































</body>
</html> 

